Healthcare

https://techpapersworld.com/wp-content/uploads/2024/12/Neo-Medicals-Spine-Care-Platform-Fully-1280x720.jpg

HealthcareNeo Medical’s Spine Care Platform Fully Approved Under EU Medical Device Regulation Directive

Neo Medical SA (Neo), a Swiss technology company specializing in spine surgery, today announced the approval of its entire product portfolio under the European Union’s (EU) Medical Device Regulation (MDR) EU 2017/745, confirming compliance with the world’s highest quality control standards for medical devices. “Full MDR certification is an important milestone in Neo’s history. From the outset, we committed to a program of long-term clinical evaluation. MDR certification acknowledges the strength and validity of our...

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2024/11/BrainCo-Intelligent-Prosthetic-Bionic--1280x720.jpg

HealthcareBrainCo Intelligent Prosthetic Bionic Hand Wins the 2024 CATON FAIR DESIGN AWARD

On October 24th, the award ceremony for the 2024 CATON FAIR DESIGN AWARD was held in Guangzhou. In this selection, BrainCo Intelligent Prosthetic Bionic Hand was honored with the highest accolade of the event, the Best of the Best Award, while another product, the BrainCo Intelligent Prosthetic Bionic Knee M3 received the Gold Award. The China Import and Export Fair is an important showcase window for the Chinese design field, and its CATON FAIR DESIGN AWARD is also known...

by business wire

https://techpapersworld.com/wp-content/uploads/2024/11/DEKAS-EXCELLENCE-IN-LASER-TECHNOLOGY-1280x720.jpg

HealthcareDEKA’S EXCELLENCE IN LASER TECHNOLOGY CONTINUES TO EXTEND ACROSS FRANCE AND NORTH AFRICA

With its focus on innovation and customer satisfaction, DEKA, which is part of the multinational El.En. group, listed on the Euronext Star segment of the Italian Stock Exchange, continues to transform the laser application landscape in several sectors, including aesthetic medicine, surgery and the restoration of works of art. Since 1981, El.En. Group has been a global leader in optoelectronics, photonics and laser engineering capabilities. The group founded its French subsidiary – DEKA Sarl –...

by business wire

https://techpapersworld.com/wp-content/uploads/2024/11/QIAGEN-Strengthens-QIAstat-Dx-With-1280x720.jpg

HealthcareQIAGEN Strengthens QIAstat-Dx With New Barcelona Site to Drive Growth in Infectious Diseases and Precision Medicine Testing

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced plans to move its QIAstat-Dx operations within the Barcelona area to a new site in Esplugues de Llobregat as part of a multi-year investment to strengthen this business. “Risk Factors in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission. ” Set to...

by business wire

https://techpapersworld.com/wp-content/uploads/2024/11/Sudden-Hearing-Loss-Study-Reaches-Milestone-1280x720.jpg

HealthcareSudden Hearing Loss Study Reaches Milestone: AudioCure Pharma Enrolls More Than Half of the Patients in AC102 Study

Berlin-based start-up AudioCure Pharma has enrolled more than 50% of the planned patients in its ongoing Phase 2 clinical trial. The aim of the study is to test the efficacy of the new compound AC102 for the treatment of sudden hearing loss. As sudden hearing loss is usually treated with non-specific corticoids that are not approved for this indication or for which there is no clear evidence of efficacy, there is an urgent need for...

by business wire

https://techpapersworld.com/wp-content/uploads/2024/11/Successful-first-Aeson®-European-User-Meeting-1280x720.jpg

HealthcareSuccessful first “Aeson® European User Meeting”, marking an important step in the deployment of CARMAT’s artificial heart

CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “Company” or “CARMAT”), announces the success of its first “Aeson® European User Meeting”, held on 21 and 22 November 2024 in Chantilly, near Paris. Strong and promising interest in Aeson® from the French and international medical community The forum brought together more than 100 European leaders...

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2024/11/Caris-Life-Sciences-Showcases-1-1280x720.jpg

HealthcareCaris Life Sciences Showcases Data Demonstrating the Clinical Value of Clonal Hematopoiesis Identification and Subtraction in Liquid Biopsy to Improve the Accuracy of Treatment Recommendations

Caris Life Sciences® (Caris), a leading next-generation AI TechBio company and precision medicine pioneer, today announced the presentation of data highlighting the clinical value of subtracting clonal hematopoiesis (CH) mutations from liquid biopsy profiling results to avoid incorrect treatment recommendations. Caris generated the findings, in collaboration with leading cancer centers, including those within the Caris Precision Oncology Alliance™ (Caris POA), and presented the data on November 23, 2024, at the International Society for Liquid Biopsy (ISLB) 6th Annual Congress....

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2024/11/Common-Thyroid-Medicine-1280x720.jpg

HealthcareCommon Thyroid Medicine Linked to Bone Loss

Levothyroxine, the second most commonly prescribed medication among older adults in the U.S., may be associated with bone loss, according to a study being presented next week at the annual meeting of the Radiological Society of North America (RSNA). Levothyroxine, marketed under multiple brand names including Synthroid, is a synthetic version of a hormone called thyroxine and is commonly prescribed to treat the condition hypothyroidism, or underactive thyroid. In people with hypothyroidism, the thyroid gland does not produce enough...

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2024/11/Roche-receives-FDA-approval-for-1280x720.jpg

HealthcareRoche receives FDA approval for first companion diagnostic to identify patients with biliary tract cancer eligible for HER2-targeted treatment with ZIIHERA

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the U.S. Food and Drug Administration (FDA) approval of a label expansion into biliary tract cancer (BTC) for the PATHWAY® anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody* test. This test is now the first and only FDA-approved companion diagnostic to aid in the assessment of HER2-positive status to identify BTC patients who are eligible for treatment with Jazz Pharmaceuticals’ ZIIHERA® (zanidatamab-hrii). PATHWAY HER2 (4B5) assay for biliary tract cancer HER2 is a...

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2024/11/Bioretec-Signed-1-1280x720.jpg

HealthcareBioretec signed a new sales and distribution agreement to accelerate the commercialization of RemeOs™ Trauma Screw in the U.S. civilian hospital market

Bioretec Ltd, a pioneering company dedicated to advancing biodegradable orthopedic implants, is moving ahead with the next phase of the commercialization of its innovative RemeOs™ Trauma Products in the U.S. market. As a continuation to the previously signed logistics agreement with GlobalMed Logistix, Bioretec strengthens now its commercialization efforts by signing a new sales and distribution agreement with Tri-State Biologics (TSB), which is a distributor of medical and surgical products based in New Jersey. TSB is a...

Newer Posts

Older Posts